A mathematical study of the interaction between oxygen and lactate in an in-vivo and in-vitro tumor

Gopinath Sadhu^{a,*}, D C Dalal^a

^aDepartment of Mathematics, Indian Institute of Technology Guwahati, Guwahati, India

Abstract

Micro-environmental acidity is a common feature of the tumor. One of the causes behind tumor acidity is lactate production by hypoxic cells of the tumor. Hypoxia is a direct result of the establishment of oxygen gradients. It is commonly observed in the tumor in an in-vitro experimental setup and also in-vivo situation. Here, we propose a mathematical model to analyses the production of lactate by hypoxic cells, and it is used as an alternative fuel by normoxic cells in tumor tissue in-vitro and in-vivo conditions. In this article, we study the effects of unequal oxygen concentration at the tumor on the lactate concentration profile is examined. The results have good agreement with experimental data and align with the theoretical findings of previous studies. The analytical results show that lactate levels are elevated in an in-vivo tumor compared to that in an in-vitro tumor. Also, during the onset of necrotic core formation, the effects of necrotic core on lactate levels are noticed. Knowledge of the lactate status in a patient's tumor may be helpful in choosing the rightful and precious medicines for cancer treatment.

Keywords: Solid tumor, oxygen, lactate, diffusion, asymmetric tumor

1. Introduction

Cancer is the second leading cause of death in the world, following heart disease. In the early stages of cancer, a genetically flawed cell begins to proliferate indefinitely in an uncontrolled manner and a mass of cells, known as a tumor is formed. The nutrients supplied by pre-existing blood vessels maintain the viability of tumor cells. As the tumor grows in size, a gradient of nutrients, particularly oxygen, is generated in the tumor core. This is due to the cells that reside near the source of oxygen consume a greater fraction of the oxygen concentration. Tumor cells require the necessary energy in a faster time compared to healthy cells. As a result, tumor cells choose different pathways to generate energy in order to maintain their uncontrollable proliferative ability. In healthy cells, energy in the form of adenosine tri-phosphate (ATP) is produced from glucose metabolism by oxidative phosphorylation (OXPHOS). Tumor cells, on the other hand, rely on aerobic glycolysis (the conversion of glucose into lactate in the presence of oxygen) for ATP production. This fact was observed by Nobel Laureate Otto Warburg a century ago [29]. The unifying feature of this altered metabolism increases glucose absorption and lactate fermentation,

^{*}Corresponding author

Email address: gsadhu@iitg.ac.in (Gopinath Sadhu)

which ultimately aids cancer progression. Highly acidic in the tumor microenvironment is the hallmarks of cancer progression [12, 9]. It promotes tumor invasion, metastasis, and therapeutic failure, particularly chemo-resistance [17, 25].

Mathematical models aid in understanding the underlying mechanism of biological phenomena [24, 31]. Al-Husari and Webb [1] investigated the role of lactate and H+ ions in regulating intracellular pH using a dynamical system. The same group also investigated the effects of oxygen and pH on tumor growth and morphology [2]. They observed that oxygen and extracellular pH influence tumor cellular growth and phenotype transformation. Gatenby et al. [11] formulated an acid-mediated tumor invasion continuum model which provides a simple mechanism for coupling altered glucose metabolism with tumor cells' ability to produce invasive malignancies. Acidity also influences the tumor cell-cell cycle and the development of necrotic core [27]. As a result, micro-environmental acidity significantly impacts progression and plays a role in therapeutic failure.

For glucose metabolism, tumor cells in the oxygen-rich region depend primarily on OXPHOS, whereas cells in the hypoxic region of the tumor depend on anaerobic phosphorylation and generate lactate abundantly. As a result, hypoxic region is the primary source of lactate in tumor tissue [22]. The oxygen concentration in the tissue is high in the vicinity of the oxygen source site (e.g., the local pre-existing blood vessel in the case of an avascular tumor) and gradually decreases with the diffusional distance from the oxygen source. Many mathematical models in existing literature tend to overlook crucial and realistic scenarios when it comes to the dynamics of tumor growth. These models generally make the simplifying assumption that tumor tissue uniformly maintains a constant oxygen concentration at its boundaries. Consequently, they have explored the intricate interplay of acidosis within tumors and its impact on both tumor growth and the generation of metabolic waste [8, 27, 6, 30]. Fiandaca et al. [10] recently developed a mathematical model to study the effects of acidosis on tumor growth under unequal oxygen concentrations at the tumor boundaries and they assumed a lactate concentration threshold above which cell death occurs. However, as tumor biology advances, scientists have discovered that lactate is more than just a byproduct of glucose synthesis, and the role of lactate is not limited to healthy tissue damage. Instead, lactate acts as a metabolic fuel for well-oxygenated tumor cells or a signaling molecule for spreading network, as discussed in the articles [14, 4]. According to Sonveaux et al. [26], lactate is a major substrate that fuels the oxidative metabolism of oxygenated tumor cells.

In this article, we have proposed a one-dimensional mathematical model to understand the lactate and oxygen interplay under the assumption that lactate acts as an alternative fuel in the oxygen-rich region of a tumor for both in-vivo and in-vitro situations. This model is solved analytically. The presented model has the ability to compute the sizes of both pre-necrotic and fully developed tumors. Also, in the current study, the lactate and oxygen dynamics with various size of tumor are explored qualitatively. The effects of the presence of the necrotic core in tumor on lactate accumulation is examined. Our results are consistent with experimental observations. Lactate plays a crucial role in tumor progression, invasion and disease prognosis. Our results may help clinicians to plan therapies and pharmacologists to design drugs for maximum benefits.

2. The formulation of problem

2.1. Physical background

Oxygen is a pivotal component of cell respiration. Oxygen diffuses into the tissue domain from blood vessels. In case of an avascular tumor, the oxygen demand is fulfilled by the nearby blood vessels. As the tumor grows, oxygen shortage is sensed in the region away from blood vessels. In that region, tumors have a threshold value of oxygen concentration C_H ; below that, tumor cells lose their proliferation ability but they remain viable. This region is known as hypoxic region (i.e., $C \leq C_H$, where C represents oxygen concentration). For large tumors, oxygen concentration reaches a threshold value C_N ; as a results, tumor cells become dead. In a region, where $C \leq C_N$ is maintained, is known as the necrotic region. So, it can be assumed that oxygen is consumed by tumor cells that are present in a viable state. In the hypoxic region, glucose metabolism of tumor cells shifts toward anaerobic metabolism, producing lactate as the main byproduct. So, lactate can be considered as a pivotal contributor to the acidification of the tumor ecosystem. Tumor cells in well-oxygenated regions uptake that lactate as an alternative metabolic fuel.

2.2. Governing equations

Oxygen diffusion equation: The steady-state oxygen transport is given as [16]

$$0 = D_c \frac{d^2 C}{dx^2} - \gamma_c C H (C - C_N), \qquad (1)$$

where C is the oxygen concentration, D_c is the diffusion coefficient and γ_c is the rate at which the tumor cells consume oxygen. Last term of the right hand side (RHS) of Eq. (1) interprets that oxygen is only consumed by viable cells and H(x) is the Heaviside function and defined as

$$H(x) = \begin{cases} 1, \ x > 0, \\ 0, \text{ otherwise.} \end{cases}$$

Lactate diffusion equation: The steady-state lactate transport is given as

$$0 = D_l \frac{d^2 L}{dx^2} + kLH(C - C_N)H(C_H - C) - \gamma_l LH(C - C_H) + dH(C - C_N),$$
(2)

where L is the lactate concentration, D_l is the diffusion coefficient. The second term on the RHS represents that lactate acid is produced by tumor cells in hypoxic region (i.e, $C_N \leq C \leq C_H$) only with the rate k. The third term on the RHS of Eq. (2) denotes that lactate is consumed by the tumor cells in the rich-oxygen area (i.e., $C \geq C_H$) of the tumor with the rate γ_l . Lactate can be produced even in aerobic conditions [7] and also through other means by live cells. The last term in the equation, represented by d, accommodates this observation.

2.3. Boundary conditions

The boundary conditions of the model equations are guided by in-vitro and in-vivo circumstances.

In-vivo case: When the tumor is present in an in-vivo environment, nutrient availability is higher near the source than that away from the source. So, oxygen concentrations are unequal

at boundaries. Lactate generated from glycolysis has a higher chance of being flushed out at the oxygen source edge as this edge is very near to the blood vessel. Lactate accumulation starts far from the oxygen source site. Hence, "no flux" boundary condition is imposed for lactate at the that boundary [10].

$$C(0) = C_l, C(R) = C_r \quad \text{with } C_l > C_r \tag{3}$$

$$L(0) = L^*, \ \frac{dL}{dx} = 0 \ \text{ at } \ x = R,$$
 (4)

where C_l , C_r are oxygen concentrations at left and right boundaries and L^* is the lactate concentration at blood vessel.

In-vitro case: When a tumor presents in an in-vitro environment, the availability of nutrients (in the present study, oxygen) is limitless at both the boundaries. The metabolic waste, like lactate, is flushed out through the edges. For the sake of simplicity, lactate is flash out in similar way as in in-vivo situation. Hence, the reasonable boundary conditions are considered as,

$$C(0) = C(R) = C_l,\tag{5}$$

$$L(0) = L(R) = L^*.$$
 (6)

3. Non-dimensionalized model

Let R be the length of the tissue, \hat{C} be the characteristic oxygen concentration, and L_0 be the characteristic lactate concentration which is same as normal physiologic value of lactate in blood. So, the dimensionless variables are given as,

$$x' = \frac{x}{R}, \ C' = \frac{C}{\hat{C}} \text{ and } \ L' = \frac{L}{L_0}$$
 (7)

The parameters and variables are made dimensionless in the following way: $C_H = C'_H \hat{C}$, $C_N = C'_N \hat{C}$, $d' = \frac{dD_c}{\gamma_c D_l L_0}$, $C'_l = \frac{C_l}{\hat{C}}$, $C'_r = \frac{C_r}{\hat{C}}$ and $\phi = R \sqrt{\frac{\gamma_c}{D_c}}$, where ϕ is the Thiele modulus. For the sake of simplicity, the 'prime' symbol is dropped over dependent and independent variables from the governing equations.

The oxygen diffusion Eq. (1) in dimensionless form becomes,

$$0 = \frac{d^2 C}{dx^2} - \phi^2 C H (C - C_N).$$
(8)

The non-dimensional form of oxygen concentrations at both the boundaries is given as,

$$C = C_l \text{ at } x = 0,$$

$$C = C_r \text{ at } x = 1.$$
(9)

It should be noted that $\hat{C} = C_l$ in the current study.

The non-dimensional form of lactate diffusion equation is given as,

$$0 = \frac{d^2L}{dx^2} + \phi^2 \alpha L H (C - C_N) H (C_H - C) - \phi^2 \beta L H (C - C_H) + d\phi^2 H (C - C_N), \quad (10)$$

where $\alpha = \frac{D_c k}{D_l \gamma_c}$, $\beta = \frac{D_c \gamma_l}{D_l \gamma_c}$ are two non-dimensional numbers. Here, it should be noted that $L_0 = L^*$. Hence, the corresponding boundary conditions are given as

$$L(x=0) = 1, \quad \frac{dL}{dx} = 0 \text{ at } x = 1 \quad \text{(In-vivo case)},$$
 (11)

$$L(x = 0) = L(x = 1) = 1$$
 (In-vitro case). (12)

Parameter	Physical description	Dimensional value	Reference
D_c	Oxygen diffusivity	$1820 \ \mu m^2 s^{-1}$	[3]
D_l	Lactate diffusivity	$1100 \ \mu m^2 s^{-1}$	[20]
C_H	Hypoxic threshold value	5 mmHg	[13]
C_N	Necrotic threshold value	$0.2 - 0.5 \ mmHg$	[13]
γ_c	Oxygen consumption rate	$0.5685 \ s^{-1}$	Estimated
γ_l	Lactate uptake rate	$1.3715 \ s^{-1}$	Estimated
k	Rate of lactate production	$0.06322 \ s^{-1}$	Estimated
	in anaerobic glycolysis		
d	Lactate produce by other	$0.015 \ mMs^{-1}$	[21]
	than anaerobic glycolysis		
C_l	Oxygen concentration	$1.43 \times 10^{-2} mM$	[13]
	near the blood vessel		
L_0	Lactate in blood vessel in	2 mM	[15]
	normal physiologic condi-		
	tion		

Table 1: Parameters values.

4. Analytical Solution

The governing equations are solved with the help of analytical methods. Typically, when a tumor reaches a size beyond a few millimeters, it undergoes spatial differentiation into three distinct zones: a normoxic region characterized by sufficient oxygen levels $(C \ge C_H)$, a hypoxic region with moderate oxygen deficiency $(C_N < C < C_H)$, and a necrotic region experiencing severe hypoxia $(C \le C_N)$. At this stage, the tumor is considered fully developed. Assuming that ϕ i.e., length of tumor tissue R is large enough that the tumor is fully developed. Suppose $x_{H,l}$ and $x_{H,r}$ are the interface points of hypoxic region and normoxic region, and $x_{N,l}$ and $x_{N,r}$ are the interface points of necrotic region and hypoxic region, where l denotes the left side and r denotes the right side point in Figure 1a-1b. The positions of these interface points (i.e., $x_{N,l}, x_{N,r}, x_{H,l}, x_{H,r}$) remain undetermined. It is assumed that oxygen is consumed by live tumor cells. The oxygen diffusion equation (8) for a fully developed tumor can be rewritten as,

$$0 = \frac{d^2C}{dx^2} - \phi^2 C, \quad x \in [0, x_{N,l}] \cup [x_{N,r}, 1], \\ 0 = \frac{d^2C}{dx^2}, \quad x \in [x_{N,l}, x_{N,r}].$$
(13)



Figure 1: The schematic region of a tumor (a) having only hypoxic region, not necrotic core at center and (b) tumor have necrotic core and hypoxic region (fully developed tumor).

Using boundaries conditions $C(0) = C_l$, $C(1) = C_r$, $C(x_{N,l}) = C_N$ and $C(x_{N,r}) = C_N$, the solution of Eqs. (13) are given as,

$$C(x) = \begin{cases} \frac{1}{\sinh(\phi x_{N,l})} \left(C_l \sinh(\phi(x_{N,l} - x)) + C_N \sinh(\phi x) \right), & 0 \le x \le x_{N,l} \\ C_N, & x_{N,l} \le x \le x_{N,r} \\ \frac{1}{\sinh(\phi(1 - x_{N,r}))} \left(C_r \sinh(\phi(x - x_{N,r})) + C_N \sinh(\phi(1 - x)) \right) & x_{N,r} \le x \le 1. \end{cases}$$
(14)

At the interface points $x_{N,l}, x_{N,r}$, it is assumed that C has continuous fluxes. Using this criteria in Eq. 14, we have

$$x_{N,l} = \frac{1}{\phi} \ln\left(\frac{C_l + \sqrt{C_l^2 - C_N^2}}{C_N}\right),$$
(15)

$$x_{N,r} = 1 - \frac{1}{\phi} \ln \left(\frac{C_r - \sqrt{C_r^2 - C_N^2}}{C_N} \right).$$
(16)

The question remains that what is the maximum value of ϕ for which tumor does not have any necrotic region i.e., oxygen concentration value attains C_N at a point in the tumor region. That means C has a minimum value C_N at a single point in [0, 1].

Prior to the formation of necrotic region in the tumor, the corresponding oxygen concentration is given as,

$$C(x) = \frac{1}{\sinh(\phi)} \left(C_r \sinh(\phi x) + C_l \sinh(\phi(1-x)) \right) \text{ in } x \in [0,1].$$
 (17)

C in Eq. (17) has minimum value at

$$x_{min} = \frac{1}{2\phi} \ln \left(\frac{\frac{C_l}{C_r} e^{\phi} - 1}{1 - \frac{C_l}{C_r} e^{-\phi}} \right).$$
(18)

The minimum value of C can not exceed C_N . By solving $C(x_{min}) = C_N$, one can get the corresponding value of ϕ (says it is ϕ_{max}).

For an in-vivo case $(C_l \neq C_r)$, $C(x_{min}) = C_N$ becomes a transcendental equation of ϕ , which

is given as,

$$AC_N^2 \cosh(3\phi) - (4C_l^2 + C_N^2(1+A^2))\cosh(2\phi) + (8C_l(C_r + 2AC_l) - AC_N^2)\cosh(\phi) = 4C_l^2 + 2(C_r + 2AC_l)^2 - C_N^2(1+A^2),$$
(19)

where $A = \frac{C_l}{C_r}$. This equation is solved by Newton-Rapshon method to obtain the approximate values of ϕ_{max} .

For in-vitro case $(C_l = C_r)$, $x_{min} = \frac{1}{2}$ (from Eq. 18) and the corresponding $\phi_{max} = 2 \cosh^{-1}(\frac{C_l}{C_N})$ (from Eq. (19)).

From these results, one can find that the maximum length R_{max} (from dimensionless Thiele modulus ϕ_{max}) of the tumor before formation of the necrotic core for both in-vivo and in-vitro cases if C_N , C_l and C_r are explicitly known.

The interface points $x_{H,l}$ and $x_{H,r}$ between normoxic and hypoxic regions can be easily obtained from Eqs. (14) and (17) by putting $C = C_H$ for a tumor before and after the formation of the necrotic core in an in-vivo and in-vitro situations.

Lactate dynamics: Here, lactate dynamics is examined within a tumor tissue for two situations (i) pre-necrotic and (ii) post-necrotic under in-vivo and in-vitro scenarios.

In the case (i), before tumor develops necrotic core (i.e., for $\phi \leq \phi_{max}$), tumor tissue can be categorized into three parts. The central part is occupied by hypoxic cells and it is surrounded by normoxic cells (Figure 1a). Hence, the governing equation (10) takes the form for this case as

$$0 = \frac{d^{2}L}{dx^{2}} - \phi^{2}\beta L + d\phi^{2}, \text{ in } x \in [0, x_{H,l}] \cup [x_{H,r}, 1] \\ 0 = \frac{d^{2}L}{dx^{2}} + \phi^{2}\alpha L + d\phi^{2} \text{ in } x \in [x_{H,l}, x_{H,r}].$$
(20)

Its corresponding solutions are given as,

$$L(x) = \begin{cases} a_1 \cosh(\phi \sqrt{\beta}x) + a_2 \sinh(\phi \sqrt{\beta}x) + \frac{d}{\beta} & \text{in } x \in [0, x_{H,l}], \\ a_3 \cos(\phi \sqrt{\alpha}x) + a_4 \sin(\phi \sqrt{\alpha}x) - \frac{d}{\alpha} & \text{in } x \in [x_{H,l}, x_{H,r}], \\ a_5 \cosh(\phi \sqrt{\beta}x) + a_6 \sinh(\phi \sqrt{\beta}x) + \frac{d}{\beta} & \text{in } x \in [x_{H,r}, 1]. \end{cases}$$
(21)

The values of the coefficients a_i for i = 1, ..., 6 are determined by ensuring the continuity of L and its fluxes at the interface points.

For the case (ii), when tumor is fully developed i.e., tumor has necrotic core at center and proliferative rim at the outer side and in between tumor has hypoxic cells ($\phi > \phi_{max}$) and lactate is generated by anerobic glycolysis in regions ii, iv and it is consumed in regions i, v and not consumed

and produced in region iii in Figure 1b. The lactate diffusion Eq. (10) is rewritten as

$$0 = \frac{d^{2}L}{dx^{2}} - \phi^{2}\beta L + d\phi^{2} \text{ in } x \in [0, x_{H,l}] \cup [x_{H,r}, 1],$$

$$0 = \frac{d^{2}L}{dx^{2}} + \phi^{2}\alpha L + d\phi^{2} \text{ in } x \in [x_{H,l}, x_{N,l}] \cup [x_{N,r}, x_{H,r}],$$

$$0 = \frac{d^{2}L}{dx^{2}} \text{ in } x \in [x_{N,l}, x_{N,r}].$$
(22)

The solutions of the Eqs. (22) are given by,

$$L(x) = \begin{cases} a_1 \cosh(\phi \sqrt{\beta}x) + a_2 \sinh(\phi \sqrt{\beta}x) + \frac{d}{\beta}, & \text{in } x \in [0, x_{H,l}] \\ a_3 \cos(\phi \sqrt{\alpha}x) + a_4 \sin(\phi \sqrt{\alpha}x) - \frac{d}{\alpha}, & \text{in } x \in [x_{H,l}, x_{N,l}] \\ a_5 x + a_6, & \text{in } x \in [x_{N,l}, x_{N,r}] \\ a_7 \cos(\phi \sqrt{\alpha}x) + a_8 \sin(\phi \sqrt{\alpha}x) - \frac{d}{\alpha}, & \text{in } x \in [x_{N,r}, x_{H,r}] \\ a_9 \cosh(\phi \sqrt{\beta}x) + a_{10} \sinh(\phi \sqrt{\beta}x) + \frac{d}{\beta}, & \text{in } x \in [x_{H,r}, 1]. \end{cases}$$
(23)

At the interface points i.e., at $x = x_{H,l}, x_{H,r}, x_{N,l}, x_{N,r}$, L and its flux terms are continuous. Using this virtue and the boundary conditions ((4), (6)), the coefficients a_i 's (for i = 1, 2, ..., 10) can be evaluated.

5. Results

5.1. Validation with experimental observations and parameter estimation

The parameters involved in the present model are not available in a single existing experimental study. Oxygen diffusivity, lactate diffusivity, consumption rates of nutrients and production rate of lactate may not be always constant rather these are dependent on cellular composition, temperature, tumor type, tumor location and time. For the sake of simplicity, we assume that these parameters are constant throughout the study and their values are taken form the exiting literature listed in Table 1. Those parameters are not available according to present model requirement, these parameters are estimated. Oxygen partial pressure near the blood vessel in in-vivo situation remains constant and it equals to 13.5 mmHg [13]. According to Henry's law, oxygen partial pressure relates with oxygen concentration and it's solubility coefficient can be expressed by the relation, oxygen concentration = oxygen partial pressure × solubility coefficient (here, solubility coefficient is $1.05 \times 10^{-3} mM/mmHg$). This gives an estimate of C_l as $1.43 \times 10^{-2} mM$. The oxygen consumption rate of tumor cells is estimated by the least square fitting to the spatial data of Helmlinger et al. [13]. It gives Thiele modulus $\phi = 7.07$ and non-dimensional necrotic threshold value as 0.03488. It follows that $\gamma_c = 0.5685 s^{-1}$ with $C_N = 0.469 mmHg$. The obtained C_N is consistent with the experimental data [13].

The non-dimensional values of parameters as shown in Table 2 are utilized for subsequent analysis. It may be noted that oxygen partial pressure in an in-vitro situation is much higher than that in an in-vivo situation. In an in-vitro case, $C_l = C_r$ is maintained always. However, in an in-vivo situation, C_r and C_l are not equal. Hence, C_r is treated as a model parameter in the current study to visualize the effects of oxygen gradient on lactate dynamics.



Figure 2: Comparison of present simulation results with the results of Helmlinger et al. [13].

Parameter	value
C_H	0.37 - 0.74
C_N	0.0348
C_l	1
α	0.184
β	3.42
d	0.021
<i>L</i> *	1

Table 2: Non dimensional parameters value are obtained using Table 1.

5.2. Oxygen profiles of a tumor prior to the formation of a necrotic core in in-vitro and in-vivo settings

The tumor tissues' oxygen profiles prior to development of a necrotic core are depicted in Figure 3. One can see that oxygen concentration falls with the increase in value of ϕ (i.e., tumor tissue length R). So, as the size of the tumor increases, the oxygen concentration starts to decrease inside the tumor. It happens because oxygen is consumed to maintain livelihood of tumor cells and mitotic cell division. It is observed that oxygen is distributed symmetrically about the center point x = 0.5 (Figure 3a). At this point, the oxygen concentration inside the tumor reaches the necrotic threshold value C_N for in-vitro situation. However, for an in-vivo situation, oxygen concentrations at the boundaries are not equal, and the corresponding oxygen profiles are displayed in Figures 3b,3c, 3d. In these cases, one can observe that oxygen concentration profiles are no longer symmetric about x = 0.5. For an in-vivo and in-vitro setting, the tumor with entire viable cells, the corresponding Thiele Modulus (ϕ_{max} from Eq. (19)) and the points (x_{min} from Eq. (18)) where oxygen concentration attains the necrotic threshold value (C_N) are shown in the Table 3.

From Table 3, one can conclude that the maximum size of the pre-necrotic tumor in an in-vitro situation is larger than that in an in-vivo situation. The point at which the oxygen concentration touches the necrotic threshold value shifts toward a lower oxygen edge.



Figure 3: Oxygen concentration profile in pre-necrotic tumor for various values of $\phi \ (\leq \phi_{max})$ with (a) $C_l = 1$, $C_r = 1$ and $\phi_{max} = 8.10$, (b) $C_l = 1$, $C_r = 0.5$ and $\phi_{max} = 7.40$, (c) $C_l = 1$, $C_r = 0.3$ and $\phi_{max} = 6.89$ and (d) $C_l = 1$, $C_r = 0.1$ and $\phi_{max} = 5.77$.

Condition	Thiele Modulus (ϕ_{max})	x_{min}
$C_l = C_r = 1$	8.10	0.5
$C_l = 1, C_r = 0.5$	7.40	0.5468
$C_l = 1, C_r = 0.3$	6.89	0.5875
$C_l = 1, C_r = 0.1$	5.77	0.70

Table 3: Thiele Modulus and the point where oxygen touches C_N .

5.3. Oxygen profiles after the formation of a necrotic core in tumor in in-vitro and in-vivo scenarios

In this section, our focus is on the effects of oxygen concentration at the tumor boundary on the generation of the necrotic core inside tumor. The tumor develops a necrotic core when Thiele Modulus (ϕ) crosses the value ϕ_{max} for the cases ($C_l = C_r = 1$; $C_l = 1, C_r = 0.5$, $C_l = 1, C_r = 0.3$ and $C_l = 1, C_r = 0.1$), which are available in Table 3. Figures 4a-4d portray the corresponding oxygen profiles. One can notice that the oxygen profile has a central plateau region in the tumor. It occurs because oxygen is not consumed at this plateau region as tumor cells die. The diameter of the necrotic core can be found as $|x_{N,r} - x_{N,l}|$ for the specific value of ϕ (> ϕ_{max}), where $x_{N,l}$ and $x_{N,r}$ are the boundary points of the necrotic core, given by the Eqs. (15) and (16) respectively. The necrotic radius is calculated for the tumor under different oxygen concentrations at the right boundary to examine the effects of oxygen concentration on necrotic core formation which is shown in Table 4. It can be concluded that the size of the necrotic core increases with the increase in the ratio of oxygen concentrations at the right and left boundaries (i.e., $\frac{C_r}{C_l}$). Hence, it hints that tumors have larger necrotic cores in an in-vivo setting than that in an in-vitro setting.

$In C_l = C_r = 1$					
$\phi (> \phi_{max})$	$x_{N,l}$	$x_{N,r}$	$ x_{N,r}-x_{N,l} $		
9	0.4501	0.5499	0.0998		
10	0.4051	0.5949	0.1898		
11	0.3683	0.6317	0.2635		
12	0.3376	0.6624	0.3248		
In $C_l = 1 \ C_r = 0.5$					
$\phi (>\phi_{max})$	$x_{N,l}$	$x_{N,r}$	$ x_{N,r} - x_{N,l} $		
9	0.4501	0.6270	0.17689		
10	0.40509	0.66431	0.25921		
11	0.36827	0.69482	0.32655		
12	0.33758	0.72026	0.38267		
In $C_l = 1 \ C_r = 0.3$					
$\phi (>\phi_{max})$	$x_{N,l}$	$x_{N,r}$	$ x_{N,r} - x_{N,l} $		
9	0.45011	0.68401	0.23389		
10	0.40509	0.71560	0.31051		
11	0.36827	0.74146	0.37319		
12	0.33758	0.76301	0.42542		
$In C_l = 1 C_r = 0.1$					
$\phi (> \phi_{max})$	$x_{N,l}$	$x_{N,r}$	$ x_{N,r}-x_{N,l} $		
9	0.45011	0.80923	0.35911		
10	0.40509	0.82830	0.42321		
11	0.368271	0.843913	0.47564		
12	0.33758	0.85692	0.51933		

Table 4: Diameter of necrotic core

5.4. Lactate profile inside the tumor prior to the formation of a necrotic core

This section focuses on the investigation of lactate accumulation in tumors considering the effects of tumor size in situations like prior to the formation of a necrotic core and after the emergence of a hypoxic region. We calculate the minimum ϕ value at which tumor begins developing a hypoxic region as per the same evaluation process employed to obtain ϕ_{max} . By substituting C_H for C_N in Eq. (19), we determine the resulting value, denoted as ϕ_{min} . For the in-vitro case $(C_l = C_r = 1), \phi_{min} = 3.3025$ and for a in-vivo case $(C_l = 1, C_r = 0.5), \phi_{min} = 2.4667$. Hence, for $\phi_{min} < \phi < \phi_{max}$, tumor has no necrotic region. When the oxygen levels fall below the hypoxic threshold at the right boundary, tumor cells in the vicinity of right boundary no longer have access to a normoxic environment. This leads to the halt of lactate consumption and the onset of a



Figure 4: Oxygen concentration profile of tumor tissue having necrotic core for various values of $\phi (\geq \phi_{max})$ with (a) $C_l = 1$ and $C_r = 1$, (b) $C_l = 1$ and $C_r = 0.5$, (c) $C_l = 1$, $C_r = 0.3$ and (d) $C_l = 1$, $C_r = 0.1$.

site for lactate production. For the cases ($C_l = 1$, $C_r = 0.5$ and $C_l = 1$, $C_r = 0.1$), ϕ_{min} is zero. The lactate profile are displayed in Figure 5 for the in-vitro and in-vivo setups. One can observe that lactate is distributed symmetrically about the tumor center and it is consumed at both the ends of the tumor for an in-vitro case (Figure 5a). Lactate starts to accumulate at central region with the increase in size of tumor i.e., size of hypoxic region. In Figures 5b, 5c and 5d, lactate profiles are portrayed corresponding to in-vivo situations of $C_l = 1$, $C_r = 0.5$; $C_l = 1$, $C_r = 0.3$ and $C_l = 1$, $C_r = 0.1$ respectively. Since, in in-vivo situations, lactate is not flushed out at the end far from blood vessel, lactate accumulation is observed at the boundary having low oxygen concentration compared with other end oxygen concentration.

From this section, one can conclude that lactate accumulation increases with the increase in oxygen gradient at the boundary.

5.5. Lactate profile after the formation of a necrotic core in tumor

In this section, we explore the lactate profile inside the tumor in the presence of a necrotic core. The tumor has a necrotic core when ϕ surpluses ϕ_{max} . After the initial formation of the necrotic core within the tumor, there is a noticeable decrease in lactate levels compared to the lactate profile observed when $\phi = \phi_{max}$. This is due to the necrotic region does not produce lactate and lactate



Figure 5: Lactate concentration profile of tumor tissue having necrotic core for various values of ϕ ($\leq \phi_{max}$) with (a) $C_l = 1$ and $C_r = 1$, (b) $C_l = 1$ and $C_r = 0.5$, (c) $C_l = 1$, $C_r = 0.3$ and (d) $C_l = 1$, $C_r = 0.1$.

gets diffused in the necrotic region. When tumor size increases, hypoxic regions increase and produce enough lactate to refill the lactate level. As a results, the lactate level rises. Lactate profiles are displayed in Figure 6. Interestingly, the impact of lactate consumption on lactate profile appears to be independent of the available lactate concentration in tumors characterized by oxygen concentrations of $C_l = 1$ and $C_r = 0.1$ at their boundaries (as illustrated in Figure 6d). This behavior is likely attributed to the substantial presence of lactate within the tumor microenvironment. But, for in-vitro case ($C_l = C_r = 1$), the impact of lactate consumption by normoxic tumor cells on lactate profile inside the tumor is observed (Figure 6a). Also, for the in-vivo cases ($C_l = 1$, $C_r = 0.5$ and $C_l = 1$, $C_r = 0.3$), lactate consumption effects is noticed (Figures 6b, 6c).

From this section, it can conclude that during the initial stages of necrotic core formation, there is an influence on lactate accumulation within the tumor. As the process advances to later stages, the presence of necrotic core appears to have a diminished impact on the lactate status within the tumor.

5.6. Analyzing lactate profiles in a non-consumption scenario

In this section, we study the lactate profile in a tumor when lactate consumption by normoxic tumor cells is not considered. In this context, the governing equation for lactate diffusion and its



Figure 6: Lactate concentration profile of tumor tissue having necrotic core for various values of ϕ ($\geq \phi_{max}$) with (a) $C_l = 1$ and $C_r = 1$, (b) $C_l = 1$ and $C_r = 0.5$, (c) $C_l = 1$, $C_r = 0.3$ and (d) $C_l = 1$, $C_r = 0.1$.

solutions are presented in **Appendix** 7. The lactate concentration profile for pre-necrotic tumors having oxygen concentration $C_r = 1$, $C_r = 0.5$, $C_r = 0.3$ and $C_r = 0.1$ at the right boundary, with $C_l = 1$ at the left boundary, are depicted in Figure 7. One can see that lactate gets accumulated at the central part of the tumor for an in-vitro tumor (Figure 7a). In contrast, lactate tends to gather at the boundary having lower level of oxygen concentration for in-vivo cases (Figures 7b, 7c, 7d). Moreover, it can be observed that the lactate level increases with the increase in size of the tumor, irrespective of the growth environment. Also, its level is high compared to that when normoxic tumor cells consume lactate as an alternative metabolic fluid.

One can conclude from this section that lactate accumulation significantly increases when lactate consumption by normoxic tumor cells is not considered. To determine the lactate profile of post-necrotic tumors where lactate consumption is absent, we followed the same process in the Appendix 7. The predicted results have similar qualitative behavior to the lactate profile in the pre-necrotic tumor (results are not shown).

6. Discussion

In this work, we propose a simplified mathematical model for lactate and oxygen interplay in a tumor in in-vitro and in-vitro situations. The effects of oxygen concentration on lactate generation



Figure 7: Lactate concentration profile without the consumption in pre-necrotic tumor for various values of ϕ ($\leq \phi_{max}$) with (a) $C_l = 1$, $C_r = 1$ and $\phi_{max} = 8.10$, (b) $C_l = 1$, $C_r = 0.5$ and $\phi_{max} = 7.40$, (c) $C_l = 1$, $C_r = 0.3$ and $\phi_{max} = 6.89$ and (d) $C_l = 1$, $C_r = 0.1$ and $\phi_{max} = 5.77$.

at the tumor boundaries are analyzed. The range of lactate concentration in the normal physiological cord is $0.5 - 2 \ \mu M$. In contrast, tumor tissue increases lactate concentration up to $40 \ \mu M$ [21]. Healthy cells produce energy by oxidative phosphorylation, and this process is slow. On the other hand, tumor cells are highly proliferative. Therefore, they need energy in quick time. To meet this need, tumor cells switch their metabolic pathway from oxidative phosphorylation to aerobic glycolysis [29]. During aerobic glycolysis, lactate is produced as a byproduct. Sonveaux et al. [26] showed that lactate is not only a metabolism byproduct but also it is consumed by tumors in oxygen-rich areas. Lactate is taking part in energy production. Lactate helps tumors to be more aggressive and creates a growth-friendly environment. Along with this, lactate can change the therapeutic effectiveness and hinder achieving maximal therapy outcomes[23]. So, analysis of lactate concentration is crucial for the disease status, therapeutic outcome and invasiveness of the disease. In reality, generation of lactate in tumor is a complex chain of network [18, 28]. However, the present model incorporates only the oxygen and lactate interplay.

In in-vitro setup, oxygen availability is limitless at the tumor boundary. In this study, we assumed that oxygen concentration remains equal at both the edges in in-vitro situation. The oxygen profile for various sizes is analyzed (Figure 3a and 4a). The oxygen concentration touches the necrotic threshold value for Thiele modulus $\phi_{max} = 8.10$ (Figure 3a) and after that tumor develops a necrotic core (Figure 4a). In the oxygen concentration profiles, after the formation of a necrotic core, a plateau region is developed about the center of the tumor. With the increase in the value of ϕ , this plateau region increases. It arises as tumor cells die and does not consume oxygen. This type of observation is also found in experimental setup [19]. However, when tumor is developed in the human body, oxygen concentrations are not equal at the boundaries. Considering unequal oxygen concentration at the boundaries, it is found that the tumor starts to form necrotic core with the value of ϕ with less value of ϕ_{max} for an in-vitro setup. The value of ϕ_{max} declines with a decline in the value of C_r at the right boundary of the tumor (Table 3). When ϕ exceeds the value of ϕ_{max} , necrotic region is developed and it is shifted towards the lower oxygen site (Figures 4d, 4c, 4b). The diameter of necrotic core increases as C_r decreases. In any in-vivo case, the necrotic region is not formed at the tumor's center. The configuration of the necrotic core experiences dynamic changes influenced by the uneven distribution of oxygen levels at its peripheries. This intricate interplays between oxygen concentration results in a corresponding asymmetry not only in the necrotic core but also in the overall tumor morphology. These phenomena closely aligns with the experimental results reported by Mueller-Klieser and Sutherland [19].

In this study, the lactate equation primarily considers the generation of lactate by hypoxic cells and its consumption by the outer layer of well-oxygenated tumor cells. The equation additionally takes into consideration the production of lactate even in aerobic environments via alternate routes, like amino acid conversion [5]. The lactate accumulation is affected due to its consumption by normoxic cells (Figures 5, 6). In the in-vitro case, lactate accumulation is not very high compared to that in in-vivo cases. This phenomenon can be attributed to two underlying facts. Firstly, in the in-vitro setup, lactate is flushed out through both the tumor boundaries. Conversely, in an in-vivo scenario, lactate is effectively flushed out only from the boundary of the tumor that is closer to the blood vessel. Secondly, in the in-vitro case, the tumor develops normoxic regions of equal length at both the boundaries. We observe the effects of the necrotic zone on lactate accumulation during the early stages of the creation of the necrotic core. During this phase, irrespective of the growth environment, there is a decrease in lactate levels. It may occur because our model directly takes into account the fact that hypoxic tumor cells are the primary source of lactate production. As the necrotic zone initiates formation, lactate diffuses towards the newly developed necrotic region. However, the lactate level increases with the size increment of the tumor. It may happen as hypoxic regions also increase with the increase in tumor size. When the oxygen concentration at the right boundary falls below the hypoxic critical value, the tumor tissue no longer will have any normoxic area on that side. As a result, the area near the right boundary of the tumor is converted into a hypoxic region and acts as a mine of lactate. So, the lactate level becomes higher in the cases $C_r = 0.3, C_r = 0.1$ compared to that for the cases $C_r = 0.5, C_r = 1$ (Figures 6a, 6b, 6c, 6d). It suggests that the lactate level in an in-vitro tumor is lower than that in an in-vivo tumor. Also, one can notice that lactate level does not surpass the experimentally observed value of 40 μM for $C_r = 1, \ C_r = 0.5$ and $C_r = 0.3$ but its value crosses the expected value for the case $C_r = 0.1$.

The overall analysis indicates that oxygen concentrations at the tumor boundaries have notable impacts on lactate accumulation .

7. Conclusions

In this article, we proposed a mathematical model to explore the lactate dynamics inside the tumor tissue. For the first time, lactate that serves as an alternative fuel source in oxygen-rich environments is incorporated, encompassing both in in-vivo and in-vitro scenarios within a single mathematical model. The model is solved analytically. The diameter of necrotic core is also calculated analytically. The following conclusive remarks are drawn from the presents study.

- 1. The size of necrotic core of a tumor in the in-vivo scenario is smaller compared to that in the in-vitro setup.
- 2. If the oxygen concentration at one boundary is less than that at the other boundary, it prompts the necrotic core to reposition itself towards the boundary with the lower oxygen concentration.
- 3. In in-vivo environments, lactate accumulation constitutes a larger fraction compared to that in an in-vitro setting.
- 4. In an in-vitro setup, lactate accumulation is predominantly found at the tumor core, while in an in-vivo environment, it shifts towards the boundary with lower oxygen concentration.
- 5. A sharp elevation in lactate concentration occurs at the right boundary the oxygen concentration falls below the hypoxic threshold.
- 6. The effects of presence of the necrotic core on lactate concentration is seen when the necrotic core starts to form. However, at a later stage, no significant impact is observed.

The acidic environmental of the tumor is a biomarker of detection of tumor tissue. Hence, tumor acidosis may help to navigate the disease site in the body.

Acknowledgments

The first author of this article thanks to the Ministry of Education, Govt. of India for research fellowship and the Indian Institute of Technology Guwahati, India for the support provided during the period of this work.

Appendix

When tumor does not consume lactate (i.e, $\beta = 0$ in Eq. (10)), then the lactate reaction diffusion equation takes the form for pre-necrotic and post-necrotic tumor as follows

$$0 = \frac{d^2L}{dx^2} + d\phi^2 \text{ for } x \in [0, x_{H,l}] \cup [x_{H,r}, 1],$$

$$0 = \frac{d^2L}{dx^2} + \phi^2 \alpha L + d\phi^2 \text{ for } x \in [x_{H,l}, x_{H,r}],$$
for pre-necrotic tumor (24)

and

$$0 = \frac{d^{2}L}{dx^{2}} + d\phi^{2} \text{ for } x \in [0, x_{H,l}] \cup [x_{H,r}, 1],$$

$$0 = \frac{d^{2}L}{dx^{2}} + \phi^{2}\alpha L + d\phi^{2} \text{ for } x \in [x_{H,l}, x_{N,l}] \cup [x_{N,r}, x_{H,r}],$$
for post-necrotic tumor
$$0 = \frac{d^{2}L}{dx^{2}} \text{ for } x \in [x_{N,l}, x_{N,r}].$$

$$(25)$$

Its corresponding solutions are given as,

$$L(x) = \begin{cases} a_1 x + a_2 - \frac{d\phi^2 x^2}{2} & \text{for } x \in [0, x_{H,l}], \\ a_3 \cos(\phi \sqrt{\alpha} x) + a_4 \sin(\phi \sqrt{\alpha} x) - \frac{d}{\alpha} & \text{for } x \in [x_{H,l}, x_{H,r}], \\ a_5 x + a_6 - \frac{d\phi^2 x^2}{2} & \text{for } x \in [x_{H,r}, 1]. \end{cases}$$
(26)

and

$$L(x) = \begin{cases} a_1 x + a_2 - \frac{d\phi^2 x^2}{2}, & \text{for } x \in [0, x_{H,l}], \\ a_3 \cos(\phi \sqrt{\alpha} x) + a_4 \sin(\phi \sqrt{\alpha} x) - \frac{d}{\alpha}, & \text{for } x \in [x_{H,l}, x_{N,l}] \\ a_5 x + a_6, & \text{for } x \in [x_{N,l}, x_{N,r}] \\ a_7 \cos(\phi \sqrt{\alpha} x) + a_8 \sin(\phi \sqrt{\alpha} x) - \frac{d}{\alpha}, & \text{for } x \in [x_{N,r}, x_{H,r}] \\ a_9 x + a_{10} - \frac{d\phi^2 x^2}{2}, & \text{for } x \in [x_{H,r}, 1]. \end{cases}$$
(27)

The coefficients a_i 's are determined using the boundary conditions at the boundary points (i.e., x = 0, 1); and L and its flux are continuous at the interface points (i.e., $x_{H,l}, x_{H,r}, x_{N,l}, x_{N,r}$).

References

- M. Al-Husari and S. D. Webb. Regulation of tumour intracellular ph: A mathematical model examining the interplay between h+ and lactate. <u>Journal of Theoretical Biology</u>, 322:58–71, 2013. doi:10.1016/j.jtbi.2013.01.007.
- [2] M. Al-Husari, C. Murdoch, and S. D. Webb. A cellular automaton model examining the effects of oxygen, hydrogen ions and lactate on early tumour growth. <u>Journal of mathematical</u> biology, 69(4):839–873, 2014. doi:10.1007/s00285-013-0719-x.
- [3] C. Androjna, J. E. Gatica, J. M. Belovich, and K. A. Derwin. Oxygen diffusion through natural extracellular matrices: Implications for estimating "critical thickness" values in tendon tissue engineering. <u>Tissue Engineering Part A</u>, 14(4):559–569, 2008. doi:10.1089/tea.2006.0361.
- [4] F. Baltazar, J. Afonso, M. Costa, and S. Granja. Lactate beyond a waste metabolite: metabolic affairs and signaling in malignancy. <u>Frontiers in Oncology</u>, 10:231, 2020. doi:10.3389/fonc.2020.00231.
- [5] H. Bossart and C. Perret. Lactate in acute conditions. In <u>International Symposium on Lactate</u> in Acute Conditions (1978: Basel). Karger, 1979.
- [6] C. J. W. Breward, H. M. Byrne, and C. E. Lewis. The role of cell-cell interactions in a twophase model for avascular tumour growth. <u>Journal of Mathematical Biology</u>, 45(2):125–152, 2002. doi:10.1007/s002850200149.
- [7] G. Brooks. Lactate production under fully aerobic conditions: the lactate shuttle during rest and exercise. In Federation Proceedings, volume 45, pages 2924–2929, 1986.
- [8] J. J. Casciari, S. V. Sotirchos, and R. M. Sutherland. Mathematical modelling of microenvironment and growth in emt6/ro multicellular tumour spheroids. <u>Cell proliferation</u>, 25(1): 1–22, 1992. doi:10.1111/j.1365-2184.1992.tb01433.x.

- [9] S. Dhup, R. Kumar Dadhich, P. Ettore Porporato, and P. Sonveaux. Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. <u>Current</u> pharmaceutical design, 18(10):1319–1330, 2012. doi:10.2174/138161212799504902.
- [10] G. Fiandaca, M. Delitala, and T. Lorenzi. A mathematical study of the influence of hypoxia and acidity on the evolutionary dynamics of cancer. <u>Bulletin of Mathematical Biology</u>, 83 (7):83, 2021. doi:10.1007/s11538-021-00914-3.
- [11] R. A. Gatenby, E. T. Gawlinski, A. F. Gmitro, B. Kaylor, and R. J. Gillies. Acid-mediated tumor invasion: a multidisciplinary study. <u>Cancer research</u>, 66(10):5216–5223, 2006. doi:10.1158/0008-5472.CAN-05-4193.
- [12] D. Hanahan and R. A. Weinberg. The hallmarks of cancer. <u>cell</u>, 100(1):57–70, 2000. doi:10.1016/S0092-8674(00)81683-9.
- [13] G. Helmlinger, F. Yuan, M. Dellian, and R. Jain. Interstitial ph and po2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. <u>Nature Medicine</u>, 3(2):177—182, February 1997. doi:10.1038/nm0297-177.
- [14] L. Ippolito, A. Morandi, E. Giannoni, and P. Chiarugi. Lactate: A metabolic driver in the tumour landscape. <u>Trends in Biochemical Sciences</u>, 44(2):153–166, 2019. ISSN 0968-0004. doi:10.1016/j.tibs.2018.10.011.
- [15] M. Laposata, editor. <u>Clinical Laboratory Reference Values</u>. McGraw-Hill Education, New York, NY, 2014.
- [16] T. D. Lewin, P. K. Maini, E. G. Moros, H. Enderling, and H. M. Byrne. A three phase model to investigate the effects of dead material on the growth of avascular tumours. <u>Mathematical</u> Modelling of Natural Phenomena, 15:22, 2020. doi:10.1051/mmnp/2019039.
- [17] C. Liu, Y. Jin, and Z. Fan. The mechanism of warburg effect-induced chemoresistance in cancer. Frontiers in oncology, 11:698023, 2021. doi:10.3389/fonc.2021.698023.
- [18] I. Lule, P.-J. D'Huys, L. Van Mellaert, J. Anné, K. Bernaerts, and J. Van Impe. Metabolic impact assessment for heterologous protein production in streptomyces lividans based on genome-scale metabolic network modeling. <u>Mathematical Biosciences</u>, 246(1):113–121, 2013. doi:10.1016/j.mbs.2013.08.006.
- [19] W. F. Mueller-Klieser and R. M. Sutherland. Influence of convection in the growth medium on oxygen tensions in multicellular tumor spheroids. <u>Cancer Research</u>, 42(1):237–242, 1982.
- [20] J. Pfeuffer, I. Tkáč, and R. Gruetter. Extracellular–intracellular distribution of glucose and lactate in the rat brain assessed noninvasively by diffusion-weighted 1h nuclear magnetic resonance spectroscopy in vivo. Journal of Cerebral Blood Flow & Metabolism, 20(4):736– 746, 2000. doi:10.1097/00004647-200004000-00011.
- [21] B. Phypers and J. T. Pierce. Lactate physiology in health and disease. <u>Continuing education</u> in Anaesthesia, critical care & pain, 6(3):128–132, 2006. doi:10.1093/bjaceaccp/mkl018.

- [22] S. J. Reshkin, M. R. Greco, and R. A. Cardone. Role of phi, and proton transporters in oncogene-driven neoplastic transformation. <u>Philosophical Transactions of the Royal Society</u> B: Biological Sciences, 369(1638):20130100, 2014. doi:10.1098/rstb.2013.0100.
- [23] V. Rossi, M. Govoni, F. Farabegoli, and G. Di Stefano. Lactate is a potential promoter of tamoxifen resistance in mcf7 cells. <u>Biochimica et Biophysica Acta (BBA)-General Subjects</u>, 1866(9):130185, 2022. doi:10.1016/j.bbagen.2022.130185.
- [24] G. Sadhu, K. S. Yadav, S. S. Ghosh, and D. C. Dalal. On impact of oxygen distribution on tumor necrotic region: A multiphase model. doi:10.48550/arXiv.2311.03394.
- [25] A. Simmons, P. M. Burrage, D. V. Nicolau Jr, S. R. Lakhani, and K. Burrage. Environmental factors in breast cancer invasion: a mathematical modelling review. <u>Pathology</u>, 49(2):172– 180, 2017. doi:10.1016/j.pathol.2016.11.004.
- [26] P. Sonveaux, F. Végran, T. Schroeder, M. C. Wergin, J. Verrax, Z. N. Rabbani, C. J. De Saedeleer, K. M. Kennedy, C. Diepart, B. F. Jordan, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. <u>The Journal of clinical investigation</u>, 118 (12):3930–3942, 2008. doi:10.1172/JCI36843.
- [27] M. J. Tindall, L. Dyson, K. Smallbone, and P. K. Maini. Modelling acidosis and the cell cycle in multicellular tumour spheroids. <u>Journal of Theoretical Biology</u>, 298:107–115, 2012. doi:10.1016/j.jtbi.2011.11.009.
- [28] R. Venkatasubramanian, M. A. Henson, and N. S. Forbes. Incorporating energy metabolism into a growth model of multicellular tumor spheroids. <u>Journal of theoretical biology</u>, 242(2): 440–453, 2006. doi:10.1016/j.jtbi.2006.03.011.
- [29] O. Warburg, F. Wind, and E. Negelein. The metabolism of tumors in the body. <u>The Journal</u> of general physiology, 8(6):519, 1927. doi:10.1085/jgp.8.6.519.
- [30] J. P. Ward and J. King. Mathematical modelling of avascular-tumour growth. <u>Mathematical Medicine and Biology: A Journal of the IMA</u>, 14(1):39–69, 1997. doi:10.1093/imammb/16.2.171.
- [31] K. S. Yadav and D. C. Dalal. A multiscale computational study of the effects of fluid flow and drug metabolism on drug delivery. <u>Computers & Mathematics with Applications</u>, 130: 58–68, 2023.